Core Viewpoint - The company, 希玛医疗, has agreed to sell 55% of its subsidiary 阿波罗 to 明达眼镜, which will involve the cancellation of a debt of 504.9 million RMB, thereby relieving the company of all liabilities related to this debt [1] Group 1: Transaction Details - The transaction will result in 阿波罗 no longer being a non-wholly owned subsidiary of the company, and the company will not hold any equity interest in 阿波罗 post-transaction [1] - The deal price includes the cancellation and return of previously issued bonds worth 504.9 million RMB [1] Group 2: Strategic Initiatives - The company has implemented several strategic measures, focusing on ophthalmic services in Hong Kong and mainland China, as well as dental and medical services in Shenzhen [1] - The sale aligns with the company's strategy to optimize internal resource utilization [1]

Group 1 - The core point of the article is that Hema Medical (03309) has agreed to transfer 55% of Apollo's total issued share capital back to Mingda Glasses, which involves the cancellation of a debt of 504.9 million RMB [1] - The transaction will relieve the company of all liabilities under the aforementioned bond, indicating a strategic move to optimize internal resource utilization [1] - Following the completion of this transaction, Apollo will no longer be a non-wholly owned subsidiary of the company, and the company will not hold any equity interest in Apollo [1] Group 2 - The company is focusing on strategic initiatives, including enhancing ophthalmic services in Hong Kong and mainland China, as well as dental and medical services in Shenzhen [1] - The sale aligns with the company's strategy to optimize the use of internal resources [1]

Financial Performance - HBC recorded total operating revenues of NOK 68.4 million in Q2 2025, down from NOK 80.4 million in Q2 2024, with net operating revenues at NOK 67.8 million compared to NOK 72.2 million year-over-year [1] - EBITDA for Q2 2025 was negative NOK 5.4 million, worsening from negative NOK 2.0 million in Q2 2024, while the first six months showed a loss of NOK 25.3 million compared to NOK 18.2 million in the same period last year [2] - Operational EBITDA for Q2 2025 was positive NOK 1.3 million, an improvement from negative NOK 2.5 million in the same quarter last year, while the first six months recorded an Operational EBITDA of negative NOK 7.0 million [2] Liquidity Position - Cash and cash equivalents decreased by NOK 3.9 million during Q2 2025, totaling NOK 68.0 million at the end of the quarter, which is an increase from NOK 25.3 million a year earlier [3] - Total liquidity, including available credit lines, reached NOK 76.5 million as of June 30, 2025 [3] Product and Market Developments - Human Nutrition B2B Sales surged 180% year-over-year to NOK 9.3 million, driven by strong demand in Europe, China, and Southeast Asia [8] - OmeGo® and ProGo® led product launches, supported by scientific validation, with ProGo® winning the "Panpan Cup" Food Maker Award in China [8] - Brilliant Salmon Oil is now available in over 25 countries, with new listings in Italy, Ireland, Taiwan, UAE, and Ecuador, and further distribution agreements in Japan, Czech Republic, and Ukraine are in progress [8] Scientific and Research Advancements - HBC emphasizes scientific evidence, leading to academic partnerships and unique health benefits, including improved iron metabolism and immune health benefits from ProGo® and OmeGo® [7] - CalGo® has shown benefits for bone and joint health, supporting healthy aging and active lifestyles, with ongoing studies and publications planned for ProGo® cognitive health in Alzheimer's [8]